Summary The aim of the study was to investigate expression of the active and inactive gelatinases (MMP-2 and -9) in colorectal neoplasia and gastric cancer compared with normal mucosa. A total of 53 colorectal cancers and corresponding normal mucosa were studied using gelatin zymography as well as 15 colorectal adenomas and 13 gastric cancers with corresponding normal mucosa. Overexpression of all the gelatinases occurs in both colorectal and gastric cancer, with activation of MMP-2 appearing to be a feature of the malignant phenotype. Overexpression of MMP-9 occurs in colorectal adenomas. The gelatinases are overexpressed in gastrointestinal neoplasia, suggesting that these enzymes may have an important role in tumour invasion and metastasis.
Matrix metalloproteinases (MMPs) are a family of enzymes whose main function is degradation of the extracellular matrix. These enzymes are present in normal healthy individuals and have a role in normal physiological processes (Jeffrey, 1991; Delaisse and Vaes, 1992; Talhouk et al, 1992; Wolf et al, 1992; Wysocki et al, 1993) . However, MMPs also act in pathological processes in which breakdown of the extracellular matrix is a key feature. Such diseases include rheumatoid arthritis (Harris, 1990) , periodontal disease (Page, 1991) and cancer.
MMPs have been functionally defined as having the following characteristics: (1) they are proteinases that degrade at least one component of the extracellular matrix; (2) they contain a zinc ion and are inhibited by chelating agents; (3) they are secreted in a latent form, requiring activation for proteolytic activity, (4) they are inhibited by tissue inhibitors of metalloproteinases (TIMPs); and (5) they share common amino acid sequences (Matrisian, 1990) . There are currently 16 members of the MMP family (Chambers and Matrisian, 1997) including the recently described membrane-bound MMPs (MT-MMP) (Sato et al, 1994) .
There has been a great deal of interest in the role of MMPs in cancer (Parsons et al, 1997) . Transformation of a tumour from the benign to the malignant state involves both breakdown of the type IV and V collagens that make up the basement membrane and invasion through the underlying connective tissue stroma. Thus, tumour cells infiltrate blood vessels and lymphatics, allowing metastasis to a distant site. As these processes involve proteolysis of the extracellular matrix and tissue remodelling, the MMPs have been implicated in tumour progression (Liotta and StetlerStevenson, 1990) , with recent evidence suggesting that MMPs are key regulators of the growth of tumours at both primary and metastatic sites (Chambers and Matrisian, 1997) . The gelatinases Received 17 November 1997 Revised 2 March 1998 Accepted 17 March 1998 Correspondence to: SL Parsons or type IV collagenases [72-kDa gelatinase (MMP-2) and 92-kDa gelatinase (MMP-9)] are the enzymes that degrade the basement membrane, and it is these enzymes that have been most studied.
Overexpression of MMPs has been demonstrated in a variety of cancers including breast (Davies et al, 1993a; Brown et al, 1993b) , prostate (Wilson and Sinha, 1993) , lung (Brown et al, 1993a) , bladder (Davies et al, 1993b) ovary (Naylor et al, 1994) head and neck (Muller et al, 1993) and pancreas (Satoh et al, 1994) . There is also immunohistochemical and zymographic evidence indicating that overexpression of MMPs occurs in colorectal and gastric cancer (Parsons et al, 1997) .
MMPs require activation in order to be biologically active. MMP-I and -9 can be activated by the family of serine proteinases (Suzuki et al, 1990; Okada et al, 1992) as well as by other members of the MMP family (Sang et al, 1995; Parsons et al, 1997) . However, MMP-2 activation is achieved only by MMPs (Crabbe et al, 1994) with MT-MMP appearing to play an important role (Sato et al, 1994; Parsons et al, 1997) .
Inhibition of MMPs represents a potential mode of therapy for gastric cancer, and the use of the orally active synthetic MMP inhibitor Marimastat (British Biotech) in patients with inoperable gastric cancer has undergone a phase I and II trial with encouraging results (Parsons et al, 1996) . A phase III trial is currently under way.
MMPs can be detected by a variety of complementary techniques. Gelatin zymography has the advantages of measuring direct enzymatic activity quantitatively (Kleiner and StetlerStevenson, 1994) and of distinguishing the active from the inactive enzyme (Brown et al, 1990; . In the present study gelatin zymography has been used to measure MMP-2 and -9 expression in colorectal tissue along the adenoma carcinoma sequence to determine whether and at what point in colorectal progression overexpression occurred. Activation of MMPs is an important step in vivo and therefore we attempted to determine at what stage in the adenoma carcinoma sequence activation takes place. Expression of MMP-2 and MMP-9 in gastric cancer compared with corresponding normal mucosa was also studied. All colorectal cancers were classified by the Dukes' and the Jass staging systems as well as the degree of differentiation. Colorectal adenomas were classified by the degree of dysplasia. Gastric cancers were classified into degree of differentiation. All normal mucosa samples were taken from the resected bowel or stomach specimens but well away from the tumour. (1998) 78 (11), [1495] [1496] [1497] [1498] [1499] [1500] [1501] [1502] . The samples were denatured at 100°C for 10 min and then cooled to 4°C and stored at -20°C until assayed for protein.
The protein was determined in the samples using a Pierce kit (Rockford, IL, USA). Standard bovine serum albumin (BSA) was made up in TBS (pH 7.6) giving a concentration range 0.2-1.2 mg ml-'. Buffer (10 ltl) of BSA standard or sample was pipetted into each well. Protein assay reagent was added (200 gl per well). The plate was covered and incubated at 37°C for 30 min and the plate was then read at 562 nm on the plate reader.
Gelatin zymography
Gelatin zymography was performed as previously described (Heussen and Dowdle, 1980; Brown et al, 1993b ) using commercially available precast zymogram gels (Novex, R and D Systems). Western blotting using monoclonal antibodies for MMP-9, pro-MMP-2 and active MMP-2 was performed to verify that the bands seen on zymography were as described (data not shown). Quantification was performed using a flat bed scanner and the Apple Macintosh software Adobe Photoshop and NIH Image as previously described (Davies et al, 1993a; Kleiner and Stetler-Stevenson, 1994) . Pure gelatinase samples were obtained from British Biotech from transfected Chinese hamster ovary cells (Chandler et al, 1995) .
Quantification of zymography in our hands was determined using serial dilutions of the pure MMP-2 gelatinase standard on multiple zymograms (Figure 1 ). As the inactive pro-MMP-2 (72-kDa gelatinase) autoactivates to the active MMP-2 (62-kDa gelatinase) in high concentrations, both these bands were combined to give one value. Correction for variation in background staining of the gel (intergel variation) was made by using the straight line equation obtained for each zymogram to calculate the pixel value for a single gelatinase value (15 ng) and correcting to the mean value. Thus, a correction factor was obtained for each zymogram allowing a single standard curve to be calculated after correction for intergel variation (Figure 2) . In all subsequent zymograms the two outer lanes contained pure gelatinase standards at 5 ng and 25 ng respectively to allow correction for intergel variation. All tissue samples were run in duplicate with tumour and corresponding normal mucosa always studied on the same zymogram in order to eliminate intergel variation as a source of error when comparing expression in tumours vs normal mucosa. Examples of zymograms for tumour and normal specimens are shown in Figure 1 .
Statistical analysis
All data were found to be non-parametrically distributed and therefore the Wilcoxon signed-rank test was used for paired data and the Mann-Whitney U-test for unpaired data.
RESULTS

Reproducibility of zymography
Computer-generated analysis of the MMP-2 bands from serial dilutions of the pure MMP-2 gelatinase revealed a linear correlation of integrated density (density multiplied by cross-sectional Colorectal cancer Fifty-three fresh-frozen colorectal cancers and their corresponding normal mucosa underwent zymography and protein determination. Frozen haematoxylin and eosin (H&E) sections were prepared and confirmed malignant cells of epithelial origin in all the cancer specimens and normal epithelium in all the normal specimens.
There was a significant overexpression of the 92-kDa (pro-MMP-9), 72-kDa (pro-MMP-2) and 62-kDa (active MMP-2) gelatinases in colorectal cancer compared with corresponding normal mucosa (P < 0.0001, P < 0.001, P < 0.0001 respectively) ( Figure 3 ). As can be seen from this figure there was expression of pro-MMP-2 in normal mucosa but virtually no expression of the active MMP-2 enzyme. The ratio of the active MMP-2 to pro-MMP-2 was 20-fold higher in carcinoma than normal (ratio of active MMP-2)/pro-MMP-2 = 0.08:1 for normal mucosa and 1.66:1 for carcinoma).
The 92-kDa gelatinase (pro-MMP-9) was overexpressed in colorectal adenomas compared with normal mucosa (P < 0.0001) but expression was less than in the carcinomas, although significance was not obtained (P = 0.067, Figure 3A) . The severely dysplastic adenomas seemed to have the highest expression of MMP-9, although the numbers were too small to perform meaningful statistical analysis. There was no overexpression of MMP-2 in adenomas compared with normal mucosa either for the pro-MMP-2 or the active form ( Figure 3B and C Gelatinase expression was also correlated with the degree of differentiation of the tumour and the Jass classification. No significant correlations were seen. Part of the Jass score includes the presence or absence of a 'conspicuous peritumoral lymphocytic infiltrate' (Jass et al, 1987) . This latter parameter did not correlate with MMP-9 expression. The MMP expression according to pathological classification is shown in Table 1 .
Gastric cancer
Sixteen gastric cancer and corresponding normal mucosa specimens underwent zymographic analysis, protein determination and H&E staining. In one of the normal mucosa specimens, histology revealed tumour present in the sample and therefore this patient was excluded. In two of the tumour sections there was no evidence of tumour and therefore these two patients were also excluded. In the sections of normal mucosa from three other patients there was evidence of intestinal metaplasia in two cases and gastritis in one case; these patients were included in the analysis.
There was a significant overexpression of the MMP-9 in gastric cancers compared with normal mucosa (P < 0.005, Figure 4A ). There was no difference in the expression of the pro-MMP-2 between gastric cancer and normal mucosa (P = 0.89, Figure 4B ) but there was overexpression of the active MMP-2 (P < 0.02, Figure 4C ). The ratio of active MMP-2 to pro-MMP-2 increased over 30-fold in gastric cancer compared with normal mucosa (ratio of active MMP-2: pro-MMP-2 = 0.04:1 for normal mucosa and 1.43:1 for carcinoma). Expression of MMP-2 in normal mucosa was the same for colorectal mucosa and gastric mucosa. However, expression of MMP-9 was higher in gastric mucosa (median = 3743) than for colorectal mucosa (median = 346, P < 0.001).
DISCUSSION
The most important finding of this study is that all the gelatinases are significantly overexpressed in colorectal cancers compared with their corresponding normal mucosa, and this evidence supports the view that the gelatinases may play a crucial role in colorectal cancer. This finding is consistent with other studies looking at the expression of the gelatinases in colorectal cancer (D'Errico et al, 1991; Hewitt et al, 1991; Pyke et al, 1993; Gallegos et al, 1995; Zeng and Guillem, 1995; Liabakk et al, 1996) . In this study there was no statistically significant correlation between gelatinase expression and any of the recognized measures of tumour aggressiveness (Dukes' stage, degree of differentiation and Jass classification). Only one previous study has shown a correlation with Dukes' stage (D 'Errico et al, 1991) . In this study immunohistochemistry was performed in 30 Dukes' A or B cancers and 10 Dukes' C cancers, with a higher proportion of Dukes' C tumours being positive for gelatinase. Immunohistochemistry is not a quantitative technique and therefore these results should be treated with caution. A recent large zymographic study showed a trend towards lower expression in Dukes' B carcinoma compared with Dukes' A and C (Liabakk et al, 1996) . These differences were the opposite of our findings of a trend towards higher expression in Dukes' B (data not shown), and overall there is no strong evidence of altered expression with Dukes' stage. MMP-9 expression showed no correlation with the presence of a lymphocytic and other inflammatory cell infiltrate as defined by Jass et al (1987) . MMP-9 is known to originate in inflammatory cells (Hibbs et al, 1985; Pyke et al, 1993; Sang et al, 1995) and it has been suggested that MMP-9 expression simply reflects the inflammatory infiltrate around the tumour rather than the characteristics of the tumour itself. The lack of correlation between MMP-9 and the lymphocytic infiltrate refutes this view.
The expression of pro-MMP-2 (72 kDa) in normal mucosa seen in this study is consistent with other work showing this enzyme to be widely expressed in normal tissues, possibly because the MMP-2 gene is known to be a 'house-keeping' gene (Matrisian, 1994) . The moderate increase in the expression of pro-MMP-2 along the adenoma carcinoma sequence ( Figure 3B ) contrasts with the dramatic change in active MMP-2, which is absent in nonmalignant tissue but increases dramatically on conversion to the malignant phenotype ( Figure 3C ). This finding is consistent with the other two zymographic studies on colorectal cancer (Yamagata et al, 1991; Liabakk et al, 1996) . This evidence supports the view that activation of MMPs is a crucial step in tumour invasiveness and clearer identification of the factors involved in this process may open up new therapeutic options for the prevention and treatment of malignant disease.
The active form of MMP-9 is the 82-kDa form. Unfortunately, this band rarely appears as a detectable band on zymography and it has been suggested that zymography is unable to differentiate the 92-from the 82-kDa band (Davies et al, 1993a) . However, this is clearly not the case, as, from our own studies and others, there is occasionally a distinct band present ( Figure IB ; Brown et al, 1993b) . It is more likely that the 82-kDa band is unstable and undergoes further cleavage to smaller fragments, although no such fragments were detected in the present study (Okada et al, 1992; Woessner, 1995) .
The finding that MMP-9 is overexpressed in colorectal adenomas suggests that expression of this enzyme may be an early step in the adenoma carcinoma sequence and that expression of the enzyme continues to rise with progression along this sequence ( Figure 3A) . Polyps that were severely dysplastic seemed to have a high expression of MMP-9, although the numbers were too small to perform any statistical analysis. In contrast to MMP-9, expression of MMP-2 was not increased in adenomas. Liabakk et al (1996) found no gelatinase expression in adenomas and these results conflict with our own. However, they have also shown no expression of inactive MMP-2 in normal mucosa and, as they admit in their discussion, it is likely that their technique is not sensitive enough to detect the low levels of MMPs in non-malignant tissue. Greater amounts of tissue per unit of sample buffer were used in tissue preparation in the present study, and this may explain the ability to detect gelatinase expression in normal mucosa and adenomas. Other studies looking at gelatinase expression in colorectal adenomas were very small, with only occasional expression seen (Newell et al, 1994; Zeng and Guillem, 1995) .
No correlations of gelatinase expression with survival is possible at present because of a limited follow-up period, and these data are awaited. One study has found overexpression of collagenase (MMP-1) to be associated with a poorer prognosis in colorectal cancer (Murray et al, 1996) , although no correlation of survival with expression of gelatinase has yet been shown (Liabakk et al, 1996) .
Gastric cancer MMP-9 and the activated form of MMP-2 are overexpressed in gastric cancer with no change in the expression of the pro-MMP-2. The reason why pro-MMP-2 does not appear to be overexpressed may be due to the fact that most of the enzyme is converted to the active form in the malignant phenotype, as in the case with colorectal cancer. These results are consistent with larger recently reported series (Nomura et al, 1995; Sier et al, 1996) . In the former study the expression of MT-MMP was studied in five of their samples and a correlation between MT-MMP expression and activation of MMP-2 to the 62-kDa form was found. This evidence suggests that MT-MMP may play a key role in the activation of certain MMPs. The latter study showed that, although there was no correlation of MMP expression with the established histological classifications of gastric cancer, there was a correlation between MMP expression and poor prognosis.
The numbers in this study were too small to draw any conclusions in relation to tumour type or grade. Two large immunohistochemical series have been reported evaluating the expression of MMP-2 in gastric cancer. Both showed increased expression in cancers compared with normal mucosa, and, whereas David et al (1994) were unable to show any correlation with any pathological features of the 87 tumours, Grigioni et al (1994) found a higher incidence of MMP-2 in diffuse cancers than intestinal, and these were associated with a worse prognosis.
Expression of MMP-9 was significantly higher in normal gastric mucosa than in normal colorectal mucosa. It is interesting to note that in the two specimens with the highest MMP-9 level, there was either gastritis or intestinal metaplasia present on histology. Gastritis implies the presence of inflammatory cells that could be the source of MMP-9 (Hibbs et al, 1985; Pyke et al, 1993) or these may represent preneoplastic lesions with consequent overexpression of MMP-9 as is seen in the colorectal adenomas ( Figure 3A) . The presence of these mucosal changes in a proportion of the normal mucosa samples is a possible explanation for the difference in expression of MMP-9 seen between normal gastric and colorectal mucosa.
In conclusion, a clear relationship between overexpression of the gelatinases and gastrointestinal malignancy has been demonstrated. MMP-2 is not overexpressed in premalignant conditions but conversion to the malignant phenotype is accompanied by overexpression of the inactive enzyme and, more importantly, cleavage to the active form. In contrast, MMP-9 is overexpressed in premalignant polyps, suggesting that this enzyme is expressed earlier on in the adenoma carcinoma sequence. This evidence suggests that inhibition of the MMPs may form a useful method of treating gastrointestinal malignancy.
